Oragenics Inc. short interest in 2018
In 2018, Oragenics Inc.'s disclosed short interest ran from 0.87% of shares outstanding on 12 Jan 2018 to 3.62% on 31 Dec 2018, a change of +2.75 percentage points. The year's high was 16.38% on 15 Oct 2018 and its low 0.87% on 12 Jan 2018, averaging 6.07% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.57 days on 28 Feb 2018. Full history: Oragenics Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2018 in figures
- Start of year
- 0.87% (12 Jan 2018)
- End of year
- 3.62% (31 Dec 2018)
- Change
- +2.75 pp
- High
- 16.38% (15 Oct 2018)
- Low
- 0.87% (12 Jan 2018)
- Average
- 6.07%
- Highest days to cover
- 4.57 (28 Feb 2018)
- SEC filings marked
- 4
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 0.87% | 1.19 | |
| 15 Feb 2018 | 1.64% | 2.29 | |
| 28 Feb 2018 | 1.48% | 4.57 | 10-K filed |
| 15 Mar 2018 | 1.94% | 1.00 | |
| 29 Mar 2018 | 2.61% | 1.00 | |
| 13 Apr 2018 | 2.34% | 1.00 | |
| 30 Apr 2018 | 3.31% | 1.00 | |
| 15 May 2018 | 2.85% | 1.00 | 10-Q filed |
| 31 May 2018 | 6.87% | 1.00 | |
| 15 Jun 2018 | 12.80% | 1.55 | |
| 29 Jun 2018 | 10.32% | 3.49 | |
| 13 Jul 2018 | 10.23% | 1.62 | |
| 31 Jul 2018 | 8.76% | 1.00 | |
| 15 Aug 2018 | 6.56% | 1.33 | 10-Q filed |
| 31 Aug 2018 | 7.41% | 1.81 | |
| 14 Sep 2018 | 6.82% | 1.00 | |
| 28 Sep 2018 | 11.73% | 1.00 | |
| 15 Oct 2018 | 16.38% | 1.00 | |
| 31 Oct 2018 | 11.10% | 1.00 | |
| 15 Nov 2018 | 3.33% | 1.00 | 10-Q filed |
| 30 Nov 2018 | 3.87% | 1.00 | |
| 14 Dec 2018 | 2.84% | 1.00 | |
| 31 Dec 2018 | 3.62% | 1.00 |
See also: Oragenics Inc.'s full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.